【摘要】 目的观察加兰他敏对增龄相关记忆障碍(AAMI)及阿尔茨海默病(AD)疗效及副反应。方法双盲法治疗增龄相关记忆障碍(MQ<90,MMSE≥24分)36例及20例阿尔茨海默病,加兰他敏与安慰剂对照组均为每次2片10毫克,每日3次,疗程2个月。以韦氏记忆量表(WMS)、MMSE、及HDS评定疗效。结果①AAMI:11例治疗组与25例对照组治后MQ增值分别为8.00±5.37及1.64±5.51(P<0.01)。治疗组2例恶心呕吐、胃部不适。②AD:加兰他敏与对照组治后MQ增值,治疗组MMSE为2.90±1.85,显著高于对照组0.50±0.97(P<0.01);治疗组HDS为3.19±2.91,显著高于对照组0.50±1.63(P<0.05);治疗组MQ为5.10±7.03,显著高于对照组0.20±4.91(t=1.95,P<0.1)。治疗组胃部不适2例,1例窦性心动过缓。结论加兰他敏对改善AAMI及AD记忆及认知功能有一定疗效且可耐受。更多还原

【Abstract】 Objective To Observe “The Efficacy and Adverse Drug Reactions of Galantamine in treating Age-associated memory impairment (AAMI) and Alzheimer’s Disease(AD)By Double Blind Method”. Methods Double blind trial was performed in 36 cases of AAMI in the aged and preaged with MQ<90(WMS)、MMSE ≥24, and 20 cases of AD. The effects were evaluated with MQ (WMS) in AAMI and MQ 、MMSE 、HDS in AD. The dosage of Galantamine and placebo all were 2 tablets(5mg/tablet) tid for 2 months. Results 1.AAMI:Significant difference of mean value of MQ increment between Galantamine 8.00±5.37 and placebo 1.64±5.51(P< 0.01).②AD:MMSE increment: Galantamine 2.90±1.85, placebo 0.50±0.97(P< 0.01);HDS increment: Galantamine 3.19±2.91, placebo 0.51±1.63(P< 0.05). MQ increment: Galantamine 5.10±7.03, placebo 0.20±4.91(t=1.95,P< 0.1). ③No significant side effects were observed. Conclusions Galantamine is effective and safe to improve memory and cognitive function in AAMI and AD.更多还原